Braveheart lands $383M IPO to take Hengrui cardio drug into Phase 3
For the second time this year, a US biotech born out of the pipeline of China-based Hengrui Pharmaceuticals is going public on the Nasdaq. Braveheart Bio priced its
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
- Cardiac drug developer Braveheart banks more than $382M in IPO biopharmadive.com